"Lamivudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
| Descriptor ID |
D019259
|
| MeSH Number(s) |
D03.383.742.680.245.500.950.500 D13.570.230.329.950.500 D13.570.230.500.925.500 D13.570.685.245.500.950.500
|
| Concept/Terms |
Lamivudine- Lamivudine
- 3TC
- 2',3'-Dideoxy-3'-thiacytidine
- 2',3' Dideoxy 3' thiacytidine
|
Below are MeSH descriptors whose meaning is more general than "Lamivudine".
Below are MeSH descriptors whose meaning is more specific than "Lamivudine".
This graph shows the total number of publications written about "Lamivudine" by people in this website by year, and whether "Lamivudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lamivudine" by people in Profiles.
-
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023 02 18; 76(4):720-729.
-
Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015 May; 15(5):1162-72.
-
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther. 2014 Oct; 40(7):804-10.
-
Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. Liver Transpl. 2013 Jun; 19(6):611-8.
-
Treatment of hepatitis B virus reactivation in a cadaveric renal transplant recipient with entecavir. Arab J Nephrol Transplant. 2013 Jan; 6(1):41-4.
-
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis. 2011 Aug; 53(4):341-8.
-
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007 Jun 21; 356(25):2614-21.
-
Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J Heart Lung Transplant. 2005 Jan; 24(1):34-7.
-
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
-
Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002 May 27; 73(10):1598-602.